Publications by authors named "Lora Kramer"

Claim this Profile
I
IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms.
Liang Zhou, Yu Zhang, Mark B Meads, Yun Dai, Yanxia Ning, Lora Kramer

Blood Adv· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
Liang Zhou, Yu Zhang, Yun Leng, Yun Dai, Maciej Kmieciak, Lora Kramer

J Hematol Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
Xin-Yan Pei, Yun Dai, Jessica Felthousen, Shuang Chen, Yukie Takabatake, Lora B Kramer

PLoS One· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Shuang Chen, Yun Dai, Xin-Yan Pei, Jennifer Myers, Li Wang, Lora B Kramer

Cancer Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Xin-Yan Pei, Yun Dai, Leena E Youssefian, Shuang Chen, Wesley W Bodie, Lora B Kramer

Blood· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.
Yun Dai, Shuang Chen, Li Wang, Xin-Yan Pei, Vanessa L Funk, Lora B Kramer

J Biol Chem· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Tri Nguyen, Yun Dai, Elisa Attkisson, Lora Kramer, Nicholas Jordan

Clin Cancer Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Yun Dai, Shuang Chen, Li Wang, Xin-Yan Pei, Lora B Kramer

Br J Haematol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Yun Dai, Shuang Chen, Rena Shah, Xin-Yan Pei, Li Wang, Lora B Kramer

Blood· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Girija Dasmahapatra, Dmitry Lembersky, Lora Kramer, Richard I Fisher, Jonathan Friedberg

Blood· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Girija Dasmahapatra, Dmitry Lembersky, Mohamed Rahmani, Lora Kramer, Jonathan Friedberg

Cancer Biol Ther· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Yun Dai, Shuang Chen, Xin-Yan Pei, Jorge A Almenara, Lora B Kramer

Blood· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Yun Dai, Shuang Chen, Lora B Kramer, Vanessa L Funk, Paul Dent

Clin Cancer Res· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Ning Gao, Lora Kramer, Mohamed Rahmani, Paul Dent, Steven Grant

Mol Pharmacol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Tri K Nguyen, Mohamed Rahmani, Ning Gao, Lora Kramer, Amie S Corbin

Clin Cancer Res· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Mohamed Rahmani, Erin Reese, Yun Dai, Cheryl Bauer, Lora B Kramer

Mol Pharmacol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Sonia C Maggio, Roberto R Rosato, Lora B Kramer, Yun Dai, Mohamed Rahmani

Cancer Res· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis.
Roy H Decker, Jay Levin, Lora B Kramer, Yun Dai, Steven Grant

Biochem Pharmacol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Louise H Cragg, Michael Andreeff, Eric Feldman, John Roberts, Anthony Murgo, Lora Kramer

Clin Cancer Res· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis